

---

## PRESS RELEASE

### **Hovione Technology's 8Shot™ inhaler chosen as finalist of Medical Design Excellence Award**

14<sup>th</sup> April 2021 – [Hovione Technology](#), a pharmaceutical specialist in innovative pulmonary device technology, announced today its new 8Shot™ Dry Powder Inhaler (DPI) has been chosen as [finalist](#) in the Drug-Delivery and Combination Products category of the 2021 Medical Design Excellence Awards (MDEA) competition. MDEA is a division of UK-based multinational Informa plc.

“The MDEA competition is a premier awards program for the medtech industry. The selection of our 8Shot™ DPI to be among the list of finalists in the Drug-Delivery and Combination products category is a great achievement for the Hovione Technology team”, said Peter Villax, Hovione Technology's CEO.

The 8Shot™ DPI is a high drug load inhaler specially designed to deliver inhaled vaccines, anti-virals, antibiotics and biologics requiring very high dose drug delivery and provides the largest delivery capability in the industry without compromising simplicity. It achieves ease of use by patients, by breaking down the delivery to the lung of the total drug dose in multiple inhalation steps for maximum therapeutic benefit and patient comfort.

“We are honored and delighted to be a finalist of the MDEA competition, together with our design and development partner [WeADD](#)”, said Dr João Ventura Fernandes, Hovione Technology's Director of Technology Development and Licensing. “This nomination recognizes our medical product design efforts with the 8Shot™ DPI to make it as attractive and as easy to use as possible to patients, a necessary step to regular use and treatment compliance.”

“We are very happy to be nominated as MDEA finalist together with Hovione Technology. This is a result of a fruitful long-term collaboration between our two companies in the design and development of medical device products”, said Agostinho Carvalho, WeADD CEO. “The 8Shot™ DPI offers a unique, patient friendly inhaler design and makes available a patented high payload DPI to pharmaceutical companies, off-the-shelf, ready to support their developments”.

For further information, please contact [info@hovionetechnology.com](mailto:info@hovionetechnology.com)

#### **About Hovione Technology**

Hovione Technology offers access to a complete portfolio of innovative, cost-effective dry powder inhalation devices – disposable, capsule-based, blister-based and large dose DPIs. With over 20 years of expertise developing innovative inhaler technology, Hovione Technology's team has been behind the first market approved disposable dry powder inhaler

for influenza treatment in Japan, the TwinCaps DPI, and the new market approved capsule DPI for Asthma and COPD management, the PowdAir Plus DPI. Millions of patients are being treated every year with Hovione Technology's innovative inhaler technology.

[www.hovionetechnology.com](http://www.hovionetechnology.com)

## **About WeADD**

WeADD is a Portuguese Company specialized in innovation, development, engineering and intellectual property in small and large appliances, machinery, functional packaging and consumer electronics in sectors such as health, sports, coffee and internet of things.

[www.weadd.com](http://www.weadd.com)